[Research Progress in Venetoclax-Based Combination Therapy in Acute Myeloid Leukaemia--Review].

Acute myeloid leukemia (AML) can be transformed by the malignant transformation of hematopoietic progenitor cells at different stages of normal myeloid cell differentiation and development, thus leading to infection, anemia, bleeding symptoms. It is a common highly heterogeneous hematologic malignancy, the incidence of which is on the rise year by year. The treatment of AML includes chemotherapy, hematopoietic stem cell transplantation and targeted therapy, etc. However, due to the highly heterogeneous nature of AML and the easy recurrence, the treatment is difficult and the cure rate is low. In recent years, combination therapy based on venetoclax has become one of the important research directions for the treatment of AML, and its efficacy has gradually received the attention of clinical researchers. This paper reviews the mechanism of action of venetoclax and its application in the current treatment of AML. Through an in-depth discussion of venetoclax and its combination therapy AML related clinical trials, the emergence of resistance mechanisms to venetoclax and potential strategies to overcome its resistance are summarized.